TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04017858

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiprofessional and educational Program prior to Total knee replacement TKA. (PARQVE TKA).
Description: Patients will participate in two days of about knee OA lectures two months apart, will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy followed by 7 sessions with the physical educators team. Following this program, patients will be operated (total knee arthroplasty).~Answer Womac, VAS, Lequesne, BMI and body fat percentage - at inclusion, one week prior to surgery, 1 and 6 months postoperatively.~Days of hospital stay will be measured by the number of nights the patients stay in the hospital postoperatively and also days in semi-intensive.~Minutes and type of physical activity - Answer at inclusion and six months postoperatively.~Perform STS30 and TUG at inclusion, one week prior to surgery, 1 and 6 months postoperatively Costs will be evaluated for cost-effectiveness and cost-utility analysis

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patients will be submitted to total knee replacement.
Description: Patients will be submitted to total knee replacement, without Multiprofessional and educational Program Answer Womac, VAS, Lequesne, BMI and body fat percentage - at inclusion, one week prior to surgery, 1 and 6 months postoperatively.~Days of hospital stay will be measured by the number of nights the patients stay in the hospital postoperatively and also days in semi-intensive.~Minutes and type of physical activity - Answer at inclusion and six months postoperatively.~Perform the STS30 and TUG at inclusion, one week prior to surgery, 1 and 6 months postoperatively
Study: NCT02609594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly application of Amnioband
Description: Weekly application of Amnioband.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biweekly application of Amnioband
Description: Biweekly application (every two weeks) of Amnioband.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care for this study is weekly multi-layer compression bandaging.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care for this study is weekly multi-layer compression bandaging.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care for this study is weekly multi-layer compression bandaging.
Study: NCT00137605

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Study: NCT02659241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Given PO
Study: NCT00137605

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Study: NCT02659241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03979001

Intervention type: OTHER
Intervention: complete ophthalmological examination
Description: collection:~* ophthalmological history and current treatments~* occular tension measurement~* measurement of visual acuity (Snellen chart)~* Axial length measurement~* Photograph of the posterior segment of the eye~* 3x3 and 6x6 macular and papillary OCT angiography
Study: NCT04354857

Intervention type: OTHER
Intervention: olfactory and gustatory tests
Description: Participants rate quality of sense of smell and taste.~Olfaction test: Sniff 10ml test tube containing 1.5ml air freshner (Mifleur Citron, Coldis, Entraigues sur Sorgues, France) and rate perception of odor.~Gustatory test: Taste a pinch and sugar and salt and rate perception of sweet or salty taste

Intervention type: OTHER
Intervention: olfactory and gustatory tests
Description: Participants rate quality of sense of smell and taste.~Olfaction test: Sniff 10ml test tube containing 1.5ml air freshner (Mifleur Citron, Coldis, Entraigues sur Sorgues, France) and rate perception of odor.~Gustatory test: Taste a pinch and sugar and salt and rate perception of sweet or salty taste
Study: NCT00867152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Darunavir 600 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Darunavir is approved by the FDA as an HIV medication in the protease inhibitor class.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine
Description: Etravirine 200 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Etravirine is approved by the FDA as an HIV medication in the non-nucleoside reuptake inhibitor class.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine
Description: Etravirine 200 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Etravirine is approved by the FDA as an HIV medication in the non-nucleoside reuptake inhibitor class.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir 100 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: Lopinavir 400 mg and ritonavir 100 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Lopinavir/Ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: GSK1349572 50 q24h for 5 days in Period 1 and for 14 days in Period 2. GSK1349572 20 mg q12h for 14 days in Period 3 if Period 3 is done. GSK1349572 is an investigational (not approved by the FDA) HIV medication in the integrase inhibitor class.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: GSK1349572 50 q24h for 5 days in Period 1 and for 14 days in Period 2. GSK1349572 20 mg q12h for 14 days in Period 3 if Period 3 is done. GSK1349572 is an investigational (not approved by the FDA) HIV medication in the integrase inhibitor class.
Study: NCT03888027

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WalkMORE group
Description: Hospitalized Internal Medicine patients will walk with trained volunteers twice daily until hospital discharge.
Study: NCT04219020

Intervention type: OTHER
Intervention: Co-created intervention
Study: NCT03110562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: oral 100 mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: oral 100 mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: oral 100 mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: subcutaneous dose of 1.3 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: subcutaneous dose of 1.3 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: subcutaneous dose of 1.3 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: oral dose of 20mg
Study: NCT02722356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin administered per oxytocin group or standard practice group (see above)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin administered per oxytocin group or standard practice group (see above)
Study: NCT04138433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real tDCS
Description: Anodal tDCS 2 ma

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham tDCS 2 ma
Study: NCT02322216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine Hydrochloride Ophthalmic Solution 0.2%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine Hydrochloride Ophthalmic Solution 0.1%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.2% Vehicle
Description: Inactive ingredients used as placebo comparator
Study: NCT02659683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium 40 mg DR Capsules of AstraZeneca LP, USA
Description: oral, cross over

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torrent's Esomeprazole Magnesium DR Capsules 40 mg
Description: oral, cross over
Study: NCT04301882

Intervention type: DRUG
Intervention: interferon combined with ribavirin (PR) antiviral therapy
Description: Patients with chronic hepatitis C treated with interferon combined with ribavirin (PR) antiviral therapy (PR therapy greater than or equal to 6 months)

Intervention type: DRUG
Intervention: direct antiviral drugs (DAAs)
Description: Patients with chronic hepatitis C treated with direct antiviral drugs (DAAs)
Study: NCT03126929

Intervention type: DIAGNOSTIC_TEST
Intervention: Coma Recovery Scale-Revised and Glasgow Coma Scale
Description: Patients have been assessed with both the Coma Recovery Scale-Revised(CRS-R) and the Glasgow Coma Scale(GCS)

Intervention type: DIAGNOSTIC_TEST
Intervention: Coma Recovery Scale-Revised and Glasgow Coma Scale
Description: Patients have been assessed with both the Coma Recovery Scale-Revised(CRS-R) and the Glasgow Coma Scale(GCS)

Intervention type: DIAGNOSTIC_TEST
Intervention: Coma Recovery Scale-Revised and Glasgow Coma Scale
Description: Patients have been assessed with both the Coma Recovery Scale-Revised(CRS-R) and the Glasgow Coma Scale(GCS)
Study: NCT04439630

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nopal fractions
Description: Nopal flour were divided in two fractions and mixed in two different test breads

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nopal fractions
Description: Nopal flour were divided in two fractions and mixed in two different test breads

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Test product without the active components
Description: Test product without the active components
Study: NCT01253681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386, paclitaxel and carboplatin
Description: 15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months.
Study: NCT03384290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRS-060
Description: Drug
Study: NCT04307472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Nudge
Description: Text message sent to patients to prompt awareness of statin eligibility before an appointment with their primary care physician

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Nudge
Description: Text message sent to patients to prompt awareness of statin eligibility before an appointment with their primary care physician
Study: NCT02865941

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortification with modular protein
Description: Modular product supplementation is based on most recent breast analysis done for the participant.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortification with modular protein
Description: Modular product supplementation is based on most recent breast analysis done for the participant.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortification with modular carbohydrate
Description: Modular product supplementation is based on most recent breast analysis done for the participant.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortification with modular carbohydrate
Description: Modular product supplementation is based on most recent breast analysis done for the participant.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortification with modular fat
Description: Modular product supplementation is based on most recent breast analysis done for the participant.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortification with modular fat
Description: Modular product supplementation is based on most recent breast analysis done for the participant.
Study: NCT02676245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Viewing Newborn Screening movie
Description: NBS Movie and printed brochure were viewed by the participants

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Viewing Newborn Screening movie
Description: NBS Movie and printed brochure were viewed by the participants

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Viewing Residual Dried Blood Spot movie
Description: DBS Movie and and printed brochure were viewed by the participants
Study: NCT04443452

Intervention type: DIAGNOSTIC_TEST
Intervention: Function Assessment (A)
Description: The participant will start in a seated position. The participant will stand up upon therapist's command, walk 3 meters, turn around, walk back to the chair and sit down. The time will stop when the participant is seated. The subject can use an assistive device. If the assistive device is used, it will be documented.~Important Note: A practice trial will be completed before the timed trial.
Study: NCT03110562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: oral dose of 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: oral dose of 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: oral dose of 20mg
Study: NCT03384290

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PRS-060 Matching Placebo
Study: NCT02274675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy for wrist and forearm
Description: Robot therapy by using a single degree reconfigurable robot to train for wrist and forearm rehabilitation training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard rehabilitation therapy
Description: Standard therapy of stroke rehabilitation including speech, physical, occupational therapies and group activities
Study: NCT02422108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Study: NCT02796911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenograft
Description: group II will be treated with CAOT combined with bovine derived xenograft (Biogen, Biotecksrl Fermi, Arcugraro VI, Italy);

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bioactive glass
Description: group III will be treated with CAOT combined with bioactive glass (Bio-Glass, Excellence Pharm Inc., Egypt).
Study: NCT01480830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Endoscopic Imaging (MEI) colonoscopy
Description: Colonoscopy using the Scope Guide system (Olympus Canada Inc.) by
Study: NCT02160808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secretin
Description: Drug to stimulate pancreatic secretion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03636451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block
Description: Women undergoing D\&C in the first trimester for either surgical abortion or miscarriage management will receive 40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block before cervical dilation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20cc 1% lidocaine with 2 units of vasopressin paracervical block
Description: Women undergoing D\&C in the first trimester for either surgical abortion or miscarriage management will be randomly assigned to receive 20cc 1% lidocaine with 2 units of vasopressin paracervical block before cervical dilation.
Study: NCT01043406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seizure Advisory System
Description: Implant of Seizure Advisory System followed by data collection for algorithm training and subsequent enabling of seizure advisory indicators.
Study: NCT04194502

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Transesophageal echocardiogram (TEE)
Description: All patients enrolled in the study will undergo a pre-operative research TEE and an intra-operative clinical TEE.
Study: NCT04570644

Intervention type: DRUG
Group type: OTHER
Intervention: ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)
Description: Drug : ALZT-OP1a~1. Mast cell stabilizer~2. Neuroinflammatory microglial modulator~ALZT-OP1b anti-inflammatory~Device: Dry Powder Inhaler The inhaler will be used to deliver ALZT-OP1a via oral inhalation for dosing on study.
Study: NCT02776696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Advanced Hybrid Closed Loop System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Closed Loop System
Study: NCT04747106

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: plasma exchange
Description: when ADP inhibition \>30%, plasma exchange, once or twice a week, 1000-1500ml plasma was exchanged for each time
Study: NCT03425890

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SURE program
Description: SURE program is a self-exercise program which aims to empower people with stroke and their caregivers to increase early UL practice outside therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SURE program
Description: SURE program is a self-exercise program which aims to empower people with stroke and their caregivers to increase early UL practice outside therapy
Study: NCT04763213

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary Angiography
Description: Patients diagnosed with occlusive or nonocclusive coronary artery disease who were treated invasive techniques (Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting)

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary Angiography
Description: Patients diagnosed with occlusive or nonocclusive coronary artery disease who were treated invasive techniques (Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting)

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary Angiography
Description: Patients diagnosed with oclusive or nonoclusive coronary artery disease who were treated medically

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary Angiography
Description: Patients diagnosed with oclusive or nonoclusive coronary artery disease who were treated medically
Study: NCT05001906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: The exercise program comprises static and dynamic breathing exercises, muscle stretching exercises and muscle strength exercises, exercises to strengthen the abdominal wall muscles, exercises to strengthen the thigh muscles - quadriceps femoris (lat. musculus quadriceps femoris), to strengthen gluteal muscles, exercises to increase pelvic mobility, exercise to improve circulation, as well as pelvic floor muscle training with relaxation techniques.
Study: NCT01496209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endomyocardial injections of allogeneic Human CSps
Description: NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of Allogeneic Human CSps.

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Endomyocardial injections of vehicle only.
Description: NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of placebo.
Study: NCT03627962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gaze-directed oculomotor training
Description: Device: Tobii PCEye~Protocol: Visual span was calculated by the distance between human-computer and dpi of fonts. Pointer speed was programmed 120pixels (5 degrees)/1sec for image drift of reading.~Dosage: 1) gaze-access required 20 to 10 degrees per fixation to activate text-to-speech (TTS) read-aloud function; about 30 repetitions of saccade and fixation.~2) gaze-directed OMT limited to 10-5 degrees. Chinese characters recognition in multiple choice format, about 60 repetitions.~Target behavior - gaze-directed access by Tobii PCEye: reading from left to right (=horizontal mouse mover); read-aloud function by gaze dwell \> 500ms. To enhance purposeful and repetitive eye movement.~Frequency: 2 session/wk x 8 wks~Duration: 30 min/session
Study: NCT03917706

Intervention type: OTHER
Intervention: Questionnaire
Description: Patients will be contacted by phone in order to fill in a questionnaire regarding their quality of life.
Study: NCT02814305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial
Description: Patient receives information on a program that may offer a financial benefit for disposing of unused opioid analgesics at a pharmacy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial
Description: Patient receives information on a program that may offer a financial benefit for disposing of unused opioid analgesics at a pharmacy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational
Description: Patient watches a video featuring narrative vignettes of patients who developed opioid dependence or abuse after using opioids postoperatively
Study: NCT00159744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asenapine
Description: Asenapine, 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine, 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, 3 weeks
Study: NCT02567344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS will be delivered at 110% rMT to the Left DLPFC with 5 seconds on, 10 seconds off for 4000 pulses.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation
Description: rTMS will be delivered via an electronic sham coil that mimics real rTMS in appearance, sound, and feeling. Pulses will be delivered to the Left DLPFC with 5 seconds on, 10 seconds off for 4000 pulses.
Study: NCT01473251

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin
Description: 1.25 mg monthly for 4 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin
Description: 1.25 mg monthly for 4 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis
Description: 0.5 mg monthly for 4 months